Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093538 | 0.86 | PTGS2 (0.56) | PTGS2MAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL4680761 | 0.86 | PTGS2 (0.53) | PTGS2MAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL4329223 | 0.83 | MAPK14 (0.69) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL23933185 | 0.80 | BRD4 (0.51) | — | |
| SCHEMBL4587731 | 0.77 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL4333428 | 0.75 | MAPK14 (0.66) | PTGS2MAPK14MAPK10MAPK11CSNK1D | |
| SCHEMBL14591605 | 0.74 | PTGS2 (0.47) | PTGS2PTGS1PAX8 | |
| SCHEMBL14626838 | 0.74 | POLB (0.53) | PTGS2MAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL6723394 | 0.73 | PTGS2 (0.68) | PTGS2PTGS1NR3C2PAX8 | |
| SCHEMBL6718388 | 0.72 | PTGS2 (0.69) | PTGS2PTGS1NR3C2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128759-A1 | Substituted isoxazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1530468-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE GMBH (DE) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004017968-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128759-A1 | Substituted isoxazole derivatives and their use in pharmaceutics | IFNG, IRF3, IL2 | PTGS2 106/4885MAPK14 3157/4885MAPK10 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.